EDGAR·FLOW

Lyell Immunopharma, Inc. — Form 4

Filed November 5, 2026 · analyzed by the Insider Agent
4 ▲ Likely positive significance 78/100
What the filing says
10% owner ARCH Venture Fund XIII, L.P. (LYEL) bought 2.3M shares (~$25.0M) on the open market (38% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating

Open-market insider purchase — historically a bullish signal.

Tradability signal
NO TRADE

No trade: positive news with only -0.3% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.80% over 4 hrs, n=371). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$15.34
+10 min · unknown
$15.24 ▼ 0.62%
+30 min · unknown
$15.90 ▲ 3.68%
+1 hr · unknown
$15.23 ▼ 0.68%
+4 hrs · unknown
$15.07 ▼ 1.73%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ LYEL · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.